In This Article:
Release Date: May 08, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Sales of advanced energy products increased by 6% to $7.9 million, indicating strong demand for single-use handpieces in the U.S.
-
The company implemented significant cost-cutting measures and a restructuring program, reducing cash burn and achieving intended outcomes.
-
Renuvion won the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener, highlighting its industry recognition.
-
The company has a strong direct-to-consumer marketing strategy, leveraging influencers and generating significant reach and PR.
-
Apyx Medical Corp (NASDAQ:APYX) has a flexible manufacturing setup with facilities in both the U.S. and Bulgaria, allowing for adaptability in response to tariffs.
Negative Points
-
Total revenue decreased by 8% to $9.4 million compared to the same period last year.
-
OEM segment sales decreased by 44.7%, primarily due to a decrease in sales volume to existing customers.
-
International revenue decreased by 17.7% year over year, indicating challenges in global markets.
-
The company is facing persistent macroeconomic headwinds impacting the global aesthetic space.
-
Net loss attributable to shareholders was $4.2 million, although this was an improvement from the previous year.
Q & A Highlights
Q: How is the progress with the Aon platform and the upgrade to the Apex One console? A: We are not commenting on the Aon pipeline yet as we await FDA clearance. However, the announcement of Aon has encouraged upgrades to the Apex One console, and we are pleased with the market response. (Charlie Goodwin, CEO)
Q: Can you provide details on the soft launch of Aon and the list of practices involved? A: We have solidified a list of 20 Aon ambassadors across the U.S. ready to go post-clearance. Once we receive FDA approval, we will install systems, train staff, and begin operations. (Charlie Goodwin, CEO)
Q: How are tariffs impacting your business, and what measures are in place to mitigate this? A: We source parts globally and have manufacturing facilities in the U.S. and Bulgaria, allowing us flexibility to adjust based on tariff impacts. (Charlie Goodwin, CEO)
Q: What is the expected impact of tariffs on margins? A: We anticipate maintaining gross margins around 60% for the year, considering current tariff situations. (Matt Hill, CFO)
Q: How are you balancing investments for the Aon launch with cash management? A: Expense control and cash management are priorities, but not at the expense of the Aon launch. Our budget includes investments to support Aon, which we see as a key differentiator for Apex Medical. (Charlie Goodwin, CEO)